1. Introduction {#sec1}
===============

Midlife obesity is associated with an increased risk for cognitive deficits in later life [@bib1], [@bib2], [@bib3], whereas midlife physical activity is associated with less cognitive decline [@bib4], [@bib5]. Behavioral interventions targeting weight loss and increased physical activity may reduce risk of cognitive impairment [@bib6], [@bib7]. However, evidence that weight loss will prevent cognitive decline is lacking. Moreover, late life weight loss can be a sign of increased risk for dementia [@bib1], and midlife weight change in either direction may be associated with greater risk for dementia later in life [@bib8], [@bib9].

Type 2 diabetes mellitus is also associated with increased risk for cognitive deficits in later life [@bib10], [@bib11], [@bib12]. Many pathologic processes may lead to this outcome, including reduced vascular function, increased inflammation, impaired glucose metabolism, and concomitant disorders, such as hypertension and depression [@bib13]. Weight loss through reduced caloric intake and increased physical activity has the potential to improve each of these conditions [@bib13], [@bib14]. Adults with type 2 diabetes may thus be particularly sensitive to any cognitive benefits of behavioral intervention for weight loss.

The Action for Health in Diabetes (Look AHEAD) study was a randomized controlled clinical trial that compared 10 years of intensive lifestyle intervention (ILI) targeting weight loss and increased physical activity to a diabetes support and education (DSE) control among overweight or obese adults with type 2 diabetes [@bib14], [@bib15]. Although no cognitive assessment was conducted at baseline, earlier cross-sectional analyses of Look AHEAD participants at year 8 showed that there were no differences in overall cognitive function between the ILI and the DSE based on a standardized interviewer-administered battery of cognitive tests [@bib16], [@bib17].

The computer-administered NIH Cognitive Toolbox has been designed to provide greater precision in cognitive assessments, particularly for domains related to processing speed and executive function [@bib18], [@bib19]. There are three primary objectives of this report. We examine whether 10 years of random assignment to ILI relative to a control condition leads to better performance on cognitive measures. We examine the consistency of any intervention effects among previously examined baseline clinical subgroups in Look AHEAD including those with higher body mass index (BMI) and previous history of cardiovascular disease (CVD) [@bib17]. We also report correlations between computer-administered and interviewer-administered cognitive test batteries to provide support for the use of the NIH Toolbox in cognitive research.

2. Methods {#sec2}
==========

The design and methods of Look AHEAD have been previously described [@bib14]. Look AHEAD was a 16-site randomized controlled trial that recruited 5145 individuals (from 2001 to 2004) who were overweight or obese and had type 2 diabetes. Participants were aged 45 to 76 years and had a BMI of \>25 kg/m^2^ (or \>27 kg/m^2^ if on insulin), glycated hemoglobin (HbA1c) \<11%, systolic/diastolic blood pressure \<160/\<100 mm Hg, and triglycerides \<600 mg/dL. All participants completed a maximal treadmill test. All Participants provided informed consent and were randomly assigned (1:1) to ILI or DSE. Local institutional review boards approved the protocol. The present study involved six Look AHEAD sites (including Baton Rouge, Denver, Memphis, Philadelphia, Pittsburgh, and Providence) that implemented two ancillary studies, the Look AHEAD Movement and Memory study and the Look AHEAD Brain study. All active participants at these sites who were willing to participate and free of contraindications (e.g., for magnetic resonance imaging \[MRI\] studies) were invited to participate. Although there were no baseline cognitive assessments in Look AHEAD, both of these ancillary studies administered paper-and-pencil tests in addition to the NIH Toolbox cognitive assessments an average of 10.9 years after randomization. The study sample comprised 1002 participants at those sites who completed both the NIH Toolbox and the face-to-face cognitive assessment (described subsequently). We attempted to administer both batteries on the same day whenever possible.

2.1. Interventions {#sec2.1}
------------------

ILI participants received dietary and physical activity goals for weight loss, and were seen weekly by study staff for 6 months and subsequently three times per month for 6 months, using a combination of group and individual contact. Thereafter, ILI participants were offered two contacts per month plus optional group meetings and refreshers, and national campaign materials [@bib15]. DSE participants were invited to attend three group sessions per year for the first 4 years, and one session per year thereafter [@bib14].

In September 2012, the study\'s sponsor (National Institute of Diabetes and Digestive and Kidney Diseases) terminated interventions based on recommendations from the trial\'s Data and Safety Monitoring Board. The reason was statistical futility for the trial\'s primary end point, which was a composite score based on death from CVD, nonfatal myocardial infarction (MI), nonfatal stroke, and hospitalization for angina [@bib20]. Observation of the cohort continues with semiannual clinic visits.

2.2. Cognitive assessments {#sec2.2}
--------------------------

The NIH Cognitive Toolbox is a computer-administered battery that was developed to harmonize cognitive assessments across studies and increase sensitivity to detect impairment and change over time [@bib18]. Reliability and validity of the performance of the Toolbox composite measures in adult populations have been reported [@bib21]. The following cognitive domains are assessed: executive function (inhibitory control/attention: Flanker Task; cognitive flexibility: Dimensional Change Card Sort), working memory (List Sorting), short-term memory (Picture Sequence), and an overall composite score that combines these outcomes (Fluid Cognition Composite) [@bib21]. We also included the Picture Vocabulary test. Centrally trained, certified, and blinded staff assisted in the administration of the Toolbox at six participating sites; 1002 of these participants provided valid data.

The interviewer-administered battery assessed attention and concentration, with the Trail Making Test-Part A [@bib22]; verbal learning and memory with the Rey Auditory Verbal Learning test [@bib23], [@bib24]; inhibitory control and divided attention with the Trail Making Test-Part B [@bib22] and the modified Stroop Color Word test [@bib25], [@bib26]; processing speed with Digit Symbol Coding [@bib27]; and global cognitive function with the Modified Mini--Mental Status Examination [@bib28].

2.3. Other measures {#sec2.3}
-------------------

Demographic characteristics and self-reported medical history were collected at baseline. Participants brought current prescription medications to update Look AHEAD medication records. Weight and height were measured in duplicate using a digital scale and stadiometer. Baseline hypertension was identified based on use of antihypertensive medications or measured blood pressure. Previous history of CVD at randomization was based on any patient self-report of MI, heart bypass surgery, coronary artery bypass graft, carotid endarterectomy, lower leg angioplasty, aortic aneurysm, congestive heart failure, or stroke. Physical fitness at baseline was estimated using the achieved metabolic equivalent level (based on treadmill speed and grade) at the time of termination of the graded exercise test. The Short-Form Health Survey 36 (SF-36) was administered to assess overall mental health [@bib29].

2.4. Statistical methods {#sec2.4}
------------------------

Potential differences by intervention group in baseline risk factors for cognitive deficits (e.g., age and education) were examined using *t*- and chi-squared tests. These comparisons were performed to assess balance across groups given that this substudy represented a *nonrandom* sample of those randomized at baseline. Partial Spearman correlations, adjusted for education (\<13, ≥13 years) were used to evaluate the association between cognitive batteries regardless of intervention arm.

Rather than using the scale scores provided by the NIH Toolbox that are adjusted to national norms, we used the unadjusted scale scores that are provided for each test and then adjusted for gender, age, race/ethnicity, among other covariates to investigate the effect of the intervention on cognition. Group differences in adjusted means for each cognitive outcome were examined using a general linear model with additional adjustments for site, time from randomization, and the following baseline characteristics: age, sex, BMI, education, race/ethnicity (African American/Black--non-Hispanic, Hispanic, non-Hispanic White, Other/Mixed race), duration of diabetes, insulin use, hypertension, history of CVD, and SF-36 score [@bib29]. From these models, adjusted means and 95% confidence intervals (CIs) were obtained within intervention group and for the difference between intervention groups.

Prespecified subgroup comparisons [@bib30] that have been previously examined in Look AHEAD were based on characteristics at the time of randomization: age (\<60, 60+ years), BMI (\<30, 30--39, ≥40 kg/m^2^), duration of diabetes (\<5, ≥5 years), and sex. For each outcome, additional comparisons were made across groups defined by the presence or absence of previous history of CVD consistent with other Look AHEAD reports [@bib17]. Heterogeneity of intervention effects among baseline subgroup levels was investigated by adding subgroup by intervention interaction terms to each model. Because we present 30 tests of subgroup hypotheses each at the 0.05 level, there is a 78% chance (i.e., 1-\[1-0.05\]^30^) that at least one of these tests would be statistically significant at an alpha level of .05, assuming independence between tests [@bib30]; however, as the outcomes are correlated, the calculation under independence would overestimate the type I error rate [@bib31]. On the basis of the inspection of observed results, additional models were fitted that contained both the BMI and previous history of CVD by intervention interaction terms to the same model.

3. Results {#sec3}
==========

The NIH Toolbox tests were administered during the Look AHEAD Brain [@bib32] or Look AHEAD Memory and Movement [@bib33] ancillary studies in a subset of 1002 participants enrolled at six sites (ILI, N = 527; DSE, N = 475; dates of administration, March 23, 2013 to September 23, 2014). Look AHEAD participants in this NIH Toolbox substudy tended to be more highly educated, have slightly lower HbA1c, and slightly higher baseline cardiorespiratory fitness compared with Look AHEAD participants who were not included. NIH Toolbox substudy participants also were less likely to be Hispanic (see [Supplemental Table 1](#appsec1){ref-type="sec"}). A comparison of individuals from the substudy sites who participated in the substudy versus those who did not participate similarly had lower HbA1c, fewer had previous history of CVD, and had higher levels of baseline cardiorespiratory fitness (see [Supplemental Table 2](#appsec1){ref-type="sec"}).

Baseline characteristics by intervention groups for participants with Toolbox assessments are presented in [Table 1](#tbl1){ref-type="table"}. The two groups were generally comparable, the ILI group had nominally, although not significantly, more participants with a history of CVD (*P* = .08) and slightly lower BMI (*P* = .07). As reported elsewhere, overall the intervention was successful, and before the termination of the trial participants randomized to the intervention achieved their cardiovascular fitness goals of reduced hypertension and diabetes control [@bib34], [@bib35].Table 1Baseline Characteristics of *n* = 1002 Participants by Intervention GroupCharacteristicIntensive lifestyle intervention (N = 527)Diabetes support and education (N = 475)*P* valueAge, mean (SD) (y)58.9 (6.6)58.7 (6.5).68Female sex, no. (%)310 (58.8%)284 (59.8%).76Race, no. (%).16 African American/Black (non-Hispanic)111 (21.1%)103 (21.7%) White387 (73.4%)333 (70.1%) Hispanic12 (2.3%)23 (4.8%) Other/Mixed17 (3.2%)16 (3.4%)Education, no. (%).13 \<13 y93 (17.6%)74 (15.6%) 13--16 y186 (35.3%)193 (40.6%) \>16 y241 (45.7%)192 (40.4%)BMI, mean (SD) (kg/m^2^)35.8 (6.0)36.2 (5.8).30BMI group, no. (%).07 \<30 kg/m^2^89 (16.9%)57 (12.0%) 30 to \<40 kg/m^2^330 (62.6%)306 (64.4%) ≥40 kg/m^2^108 (20.5%)112 (23.6%)HbA1c, mean (SD) (%)7.2 (1.1)7.2 (1.2).87HbA1c (%) group, no. (%).98 \<6.5%136 (25.8%)120 (25.3%) 6.5% to ≤7.5%237 (45.0%)214 (45.0%) \>7.5%154 (29.2%)141 (29.7%)Hypertension, no. (%)452 (85.8%)397 (83.6%).34Previous history of CVD, no. (%)80 (15.2%)54 (11.4%).08 Only MI, bypass surgery or CABG62 (11.8%)41 (8.6%) Only stroke11 (2.1%)3 (0.6%) Both MI/bypass surgery/CABG and stroke4 (0.8%)4 (0.8%) Other CVD event3 (0.6%)6 (1.3%)Diabetes duration, mean (SD) (y)6.4 (6.4)6.8 (6.4).36Diabetes duration, no. (%).25 \<5 y250 (47.4%)212 (44.6%) ≥5 y276 (52.4%)259 (54.5%)Insulin use, no. (%).55 No435 (85.0%)397 (86.3%) Yes77 (15.0%)63 (13.7%)Smoking status, no. (%).84 Never265 (50.3%)247 (52.1%) Past241 (45.7%)208 (43.9%) Present21 (4.0%)19 (4.0%)Cardiorespiratory fitness, mean (SD), METS7.4 (1.9)7.4 (2.1).90Cardiorespiratory fitness category, No. (%).61 \<7.5 METS291 (55.2%)270 (56.8%) ≥7.5 METS236 (44.8%)205 (43.2%)[^1]

Time from randomization to the single administration of the NIH Toolbox Cognitive Assessment was 10.9 years (standard deviation \[SD\] = 0.77) in the ILI group and 10.9 years (SD = 0.79) in the DSE group, with a mean age of 70 years at the time of the cognitive assessment in both groups. Among those with a history of CVD, the most common events included MI and bypass surgery or coronary artery bypass graft.

Unadjusted and adjusted means (SD) for Toolbox test outcomes are presented by intervention group in [Table 2](#tbl2){ref-type="table"}. The ILI and DSE groups had similar scores for all tests (*P* \> .05). As expected, Toolbox test outcomes were significantly correlated with the interviewer-administered measures (*P* \< .001; [Table 3](#tbl3){ref-type="table"}). Eighty-eight percent of the pairings of interviewer-administered and computer-administered tests were administered on the same day, and approximately 95% of tests were administered within 60 days of each other. When the time between tests was limited to those administered on the same day, the correlations changed little.Table 2Unadjusted and Adjusted[∗](#tbl2fnlowast){ref-type="table-fn"} Mean Scores From the NIH Toolbox by Intervention GroupOutcomeIntensive lifestyle interventionDiabetes support and educationDifference between adjusted means (95% CI)*P* value for difference between adjusted meansNUnadjusted mean (SD)Adjusted mean (95% CI)NUnadjusted mean (SD)Adjusted mean (95% CI)Flanker--inhibitory and attention51998.7 (9.2)98.9 (98.2, 99.5)47498.9 (9.4)99.0 (98.2, 99.7)0.11 (−0.90, 1.12).83Dimensional Change Card Sort51898.5 (9.7)98.6 (97.9, 99.3)46998.6 (10.0)98.7 (97.9, 99.5)0.14 (−0.94, 1.22).80List Sorting51598.1 (9.9)98.0 (97.2, 98.8)47097.9 (10.1)97.7 (96.9, 98.6)−0.27 (−1.44, 0.90).65Picture Sequence Memory50391.4 (10.4)91.4 (90.5, 92.2)45591.6 (9.9)91.4 (90.5, 92.3)0.06 (−1.17, 1.29).93Picture Vocabulary524120.3 (11.3)120.2 (119.4, 121.0)472120.0 (10.5)120.2 (119.3, 121.0)−0.03 (−1.20, 1.13).95Fluid Cognition Composite47791.9 (8.7)91.9 (91.3, 92.6)43792.1 (8.1)92.1 (91.4, 92.7)0.15 (−0.77, 1.07).75[^2][^3]Table 3Spearman Correlations Adjusted for Education Level (\<13, ≥ 13 years) and Randomization ArmMeasureNIH Cognition Toolbox computer administered measuresFlanker---Inhibitory and AttentionDimensional Change Card SortList SortingPicture Sequence MemoryPicture VocabularyFluid Cognition CompositeInterviewer-administered cognitive measures DSC[∗](#tbl3fnlowast){ref-type="table-fn"}0.480.550.360.380.290.63 Trails B[∗](#tbl3fnlowast){ref-type="table-fn"}−0.49−0.52−0.48−0.40−0.37−0.64 3MSE[∗](#tbl3fnlowast){ref-type="table-fn"}0.380.440.390.390.500.52 Delayed RAVLT[∗](#tbl3fnlowast){ref-type="table-fn"}0.260.310.300.470.280.45 Stroop[∗](#tbl3fnlowast){ref-type="table-fn"}−0.31−0.41−0.31−0.34−0.30−0.48Interviewer-administered cognitive measures administered on the same day as computer-administered tests DSC[∗](#tbl3fnlowast){ref-type="table-fn"}0.510.560.360.390.290.64 Trails B[∗](#tbl3fnlowast){ref-type="table-fn"}−0.49−0.53−0.47−0.41−0.35−0.65 3MSE[∗](#tbl3fnlowast){ref-type="table-fn"}0.370.440.390.390.510.52 Delayed RAVLT[∗](#tbl3fnlowast){ref-type="table-fn"}0.260.320.300.480.290.45 Stroop[∗](#tbl3fnlowast){ref-type="table-fn"}−0.32−0.42−0.30−0.36−0.28−0.49NIH Cognition Toolbox computer-administered measures Dimensional Change Card Sort[∗](#tbl3fnlowast){ref-type="table-fn"}0.62 List Sorting[∗](#tbl3fnlowast){ref-type="table-fn"}0.280.33 Picture Sequence Memory[∗](#tbl3fnlowast){ref-type="table-fn"}0.300.360.36 Picture Vocabulary[∗](#tbl3fnlowast){ref-type="table-fn"}0.280.310.390.23 Fluid Cognition Composite[∗](#tbl3fnlowast){ref-type="table-fn"}0.730.790.620.650.39[^4][^5]

When further explored by baseline subgroup ([Fig. 1](#fig1){ref-type="fig"} and [Supplemental Table 3](#appsec1){ref-type="sec"}), tests of interaction were only significant at the nominal .05 level for four of 30 tests. Subgroup analyses identified different intervention effects within baseline BMI groups for Picture Sequence Memory (*P* = .01), within baseline CVD groups for Picture Vocabulary (*P* = .01) and Fluid Cognition Composite (*P* = .02) measures, and within baseline age groups for Picture Vocabulary (*P* = .02). Briefly, within the highest BMI group (BMI ≥ 40), the ILI group had poorer short-term memory compared with the DSE group (Picture Sequence Memory mean difference = 3.54; 95% CI, 0.96--6.11), and in participants with previous history of CVD, language performance was poorer in the ILI group than in the DSE group (Picture Vocabulary mean difference = 3.81; 95% CI, 0.59--7.03), as was performance on the Fluid Cognition Composite (mean difference = 2.95; 95% CI, 0.36--5.54).Fig. 1Differences between intervention group means (95% CI) and tests of interaction among baseline subgroups. Estimated differences (DSE-ILI) and 95% CI obtained from least-squared means from general linear models adjusted for clinic site, time from randomization, and the following baseline characteristics: age, sex, education, race/ethnicity, duration of diabetes, insulin use, hypertension, history of cardiovascular disease, and SF-36 mental score. Interaction *P* values obtained by refitting the model with each intervention by subgroup effect added to separate models for each outcome and baseline subgroup. Abbreviations: CI, confidence interval; ILI, intensive lifestyle intervention.

4. Discussion {#sec4}
=============

We evaluated cognitive performance using the NIH Toolbox and interviewer-administered tests in a subsample of 1002 Look AHEAD participants who participated in a follow-up cognitive evaluation 10 years after randomization. NIH Toolbox cognitive outcomes were significantly correlated with interviewer-administrated cognitive measures providing further support for the validity of the NIH Toolbox, which could have important implications for where and when cognitive assessments are performed. Our findings also suggest that the effects of an ILI for adults with a previous history of CVD or with high BMI may have negative implications for cognition.

There were no intervention group differences in cognitive function measured by the Toolbox, which is consistent with previous reports regarding interviewer-administered tests completed 8 to 10 years after Look AHEAD randomization [@bib16], [@bib17] and consistent with intervention tests performed on the interviewer-administered tests within the current subset of participants (results not shown). Among those with a previous history of CVD, the ILI group performed worse than the DSE group on a language task and on the Fluid Cognition Composite. These findings are consistent with earlier Look AHEAD reports [@bib16], [@bib17] but are in contrast to results from a Look AHEAD MRI substudy that included a subsample (*n* = 319) who completed cognitive testing and MRI [@bib32]. Although total brain and hippocampal volume did not differ between groups, ILI participants had smaller white matter hyperintensity and ventricular volumes indicating better brain health roughly equivalent to 2 years younger in age [@bib32]. Similarly, in the Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes (ACCORDION MIND) study, although the lifestyle intervention group initially showed small but significant benefit in total brain volume [@bib36], later follow-up showed no differences on MRI measures between intervention groups [@bib37]. This study differed in that the follow-up period was shorter and the cohort did not consist of exclusively overweight or obese participants.

The results of a 12-study meta-analysis suggest that intentional weight loss can lead to improved cognitive function [@bib38]. Clinical trials testing the effects of physical exercise have demonstrated cognitive benefits in older adults with subjective memory complaints [@bib39] and improvements in glucose metabolism and cognition in adults with amnestic mild cognitive impairment and thus at high risk for progression to dementia [@bib40]. Our overall findings that showed no benefits of ILI on cognition and a potentially negative impact in adults with high BMI or with history of CVD are counter to expectation. It is possible that there were differential effects on participants by BMI or CVD status because of the complex associations between weight loss, cerebral blood flow, and vasodilation. Participants with a history of CVD and those who were morbidly obese may have already experienced some decrease in cognitive efficiency at baseline, possibly associated with diabetes [@bib41]. Although speculative, the consequence of this accumulation of factors may be decreased cognitive function in members of the intervention group who were morbidly obese or had a previous history of CVD at baseline (for a more detailed discussion see [@bib42]). However, as this finding also may be an artifact of multiple statistical tests, additional research is needed.

This study has both strengths and limitations. This is one of the few studies to compare performance on standardized cognitive tests with the NIH Toolbox in an older cohort of individuals with diabetes. In addition, the results support its validity and feasibility in large clinical trials with older adults. Because the cognitive assessments in Look AHEAD were administered years after the initial randomization to ILI or DSE, the study lacks a baseline evaluation of cognitive function. Although most computer-based and interviewer-based cognitive assessments were administered on the same day, for small portion of participants (5%) the two types of assessments took place up to 60 days apart. However, this variability did not alter the findings when examined in the statistical analysis. Although the analysis by baseline subgroups were determined a priori based on the number of tests performed, we cannot rule out the possibility that these results are because of chance alone [@bib30]. Because the number of participants with previous history of CVD in both the ILI and DSE groups is relatively small, CIs on intervention effects are quite wide in this group. Overall, our findings provide evidence to support the internal validity of the NIH Toolbox and utility of this computer test battery to assess cognition in older adults with type 2 diabetes.Research in Context1.Systematic review: We searched PubMed for publications from studies that used the NIH Toolbox Cognition Battery. Few publications beyond the original validation studies were found.2.Interpretation: In the Look AHEAD clinical trial, performance on the NIH Toolbox Cognition Battery was correlated with standard paper-and-pencil tests including Trail Making, the Rey Auditory Verbal Learning test, the Stroop Color Word test, Digit Symbol Coding, and the Modified Mini-Mental Status Examination. We found little difference in performance on the NIH Toolbox between intervention groups. Prespecified subgroup analysis found that those who were older at baseline, those with higher baseline body mass index, and those with a history of cardiovascular disease who were randomized to the intervention did not perform as well.3.Future directions: Although modest, our results suggest negative outcomes in certain subgroups randomized to the intervention arm of the trial. These are consistent with earlier findings and suggest the need for further investigation.
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[^1]: Abbreviations: BMI, body mass indx; CABG, coronary artery bypass graft; CVD, cardiovascular disease; METS, metabolic equivalents; MI, myocardial infarction; SD, standard deviation.

[^2]: Abbreviations: CI, confidence interval; SD, standard deviation.

[^3]: Adjusted for clinic site, time from randomization, and the following baseline characteristics: age, sex, education, race/ethnicity, duration of diabetes, insulin use, hypertension, history of cardiovascular disease, and SF-36 mental score.

[^4]: Abbreviations: DSC, Digit Symbol Coding; RAVLT, Rey Auditory Verbal Learning test; 3MSE, Modified Mini--Mental Status Examination.

[^5]: All correlations are significant at *P* \< .0001.
